{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:55:50Z","timestamp":1787993750993,"version":"build-2784847793"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>In Huntington's disease (HD), the main clinical symptoms include depression, apathy, cognitive deficits, motor deficiencies and involuntary movements. Cognitive, mood and behavioral changes may precede motor symptoms by up to 15 years. The treatment of these diverse symptoms is challenging. Tetrabenazine and deutetrabenazine are the only medications specifically approved for Huntington's chorea, but they do not affect the non-motor symptoms. For these, antidepressants, antipsychotics, and benzodiazepines have demonstrated benefit in some cases and can be used off-label. These drugs, due to sedative side effects, may negatively influence cognition. Sixteen patients having HD received a 12-week off-label cariprazine (CAR) treatment (1.5\u20133 mg\/day). Cognitive performance and behavioral changes were measured by the Addenbrooke Cognitive Examination (ACE) test, the Cognitive and Behavioral part of the Unified Huntington's Disease Rating Scale (UHDRS), and the Beck Depression Inventory (BDI). Mixed model for repeated measures was fitted to the data, with terms of visit, baseline (BL) and their interaction. Cariprazine treatment resulted in the following changes from BL to week 12, respectively: the mean score of BDI decreased from 17.7 \u00b1 10.7 to 10.0 \u00b1 10.7 (<jats:italic>p<\/jats:italic> &amp;lt;0.0097), while the Behavioral Assessment score of the UHDRS decreased from 54.9 \u00b1 11.3 to 32.5 \u00b1 15.4 (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001); ACE score increased from 75.1 \u00b1 11.0 to 89.0 \u00b1 9.3 (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001); Cognitive Verbal Fluency score from 6.2 \u00b1 2.5 to 7.7 \u00b1 2.7 (<jats:italic>p<\/jats:italic> &amp;lt; 0.0103); Symbol Digit Test from 9.2 \u00b1 6.9 to 12.3 \u00b1 8.9 (<jats:italic>p<\/jats:italic> &amp;lt; 0.0009). Mild akathisia was the most frequent side effect, presenting in 2 out of 16 patients (12.5%). We conclude that CAR had a positive effect on depressive mood, apathy and cognitive functions in patients with early stage of HD. Based on the neurobiological basis of these symptoms, CAR can improve the dopamine imbalance of the prefrontal cortex. This draws attention to the transdiagnostic approach which supports the further understanding of the similar symptomatology of different neuropsychiatric disorders and helps to identify new indications of pharmaceutical compounds.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.825532","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T06:13:15Z","timestamp":1644473595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Maria Judit","family":"Molnar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Fedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reka","family":"Csehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoly","family":"Acsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Borsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Grosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19152","DOI":"10.1038\/s41598-019-55202-x","article-title":"Assessing average somatic CAG repeat instability at the protein level","volume":"9","author":"Aviolat","year":"2019","journal-title":"Sci Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/15548627.2020.1728096","article-title":"Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease","volume":"17","author":"Franco-Iborra","year":"2021","journal-title":"Autophagy."},{"key":"B5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/biomedicines9020109","article-title":"Dopamine in health and disease: much more than a neurotransmitter","volume":"9","author":"Franco","year":"2021","journal-title":"Biomedicines."},{"key":"B6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/biom11010104","article-title":"Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders","volume":"11","author":"Kiss","year":"2021","journal-title":"Biomolecules."},{"key":"B7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1468-1331.2008.02390.x","article-title":"Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease","volume":"16","author":"van Oostrom","year":"2009","journal-title":"Eur J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain."},{"key":"B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","article-title":"Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in huntington's disease: evidence for an overactive dopaminergic brain transmission","volume":"58","author":"Garrett","year":"1992","journal-title":"J Neurochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00005072-199501000-00013","article-title":"Early loss of neostriatal striosome neurons in huntington's disease","volume":"54","author":"Hedreen","year":"1995","journal-title":"J Neuropathol Exp Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0306-4522(95)00012-8","article-title":"Iontophoresis in the neostriatum of awake, unrestraine rats: differential effects of dopamine, glutamate and ascorbate on motor- and nonmotor-related neurons","volume":"67","author":"Pierce","year":"1995","journal-title":"Neuroscience."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","article-title":"Therapeutic update on huntington's disease: symptomatic treatments and emerging disease-modifying therapies","volume":"17","author":"Dash","year":"2020","journal-title":"Neurotherapeutics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington study Group\/TETRA-HD investigators","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s40734-017-0067-x","article-title":"Tetrabenazine Vs. deutetrabenazine for huntington's disease: twins or distant cousins?","volume":"4","author":"Rodrigues","year":"2017","journal-title":"Mov Dis Clin Practice."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J Clin Mov Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","article-title":"Bupropion for the treatment of apathy in Huntington's disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial","volume":"12","author":"Gelderblom","year":"2017","journal-title":"PLoS ONE."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009444.pub3","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S109285291900083X","article-title":"The role of dopamine D 3 receptors in the mechanism of action of cariprazine","volume":"25","author":"Calabrese","year":"2020","journal-title":"CNS Spect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectrums."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data","volume":"10","author":"Stahl","year":"2020","journal-title":"Thera Adv Psychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch General Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov Dis."},{"key":"B24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-319-44775-9_6","article-title":"Addenbrooke's cognitive examinations: ACE, ACE-R, ACE-III, ACEapp, M-ACE","volume-title":"Cognitive Screening Instruments.","author":"Hodges","year":"2017"},{"key":"B25","volume-title":"Cognitive Screening Instruments: A Practical Approach.","author":"Larner","year":"2016"},{"key":"B26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder","volume":"33","author":"Fava","year":"2018","journal-title":"Int Clin Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants","volume":"77","author":"Durgam","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/03007995.2021.1932446","article-title":"The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial","volume":"37","author":"Vieta","year":"2021","journal-title":"Curr Med Res Opinion."},{"key":"B32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1017\/S1092852921000213","article-title":"Effects of cariprazine on cognition in patients with bipolar mania or mixed states: post hoc analysis from 3 randomized, controlled phase iii studies","volume":"26","author":"Mcintyre","year":"2021","journal-title":"CNS Spect."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1756286420938972","DOI":"10.1177\/1756286420938972","article-title":"Wernicke\u2013Korsakoff syndrome associated with mtDNA disease","volume":"13","author":"Jimoh","year":"2020","journal-title":"Therap Adv Neurol Dis."},{"key":"B34","first-page":"10","article-title":"Cariprazine may decrease substance abuse in patients with bipolar i disorder","volume":"36","author":"Sanders","year":"2019","journal-title":"Psychiatric Times."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajad.13241","article-title":"Case series: cariprazine for treatment of methamphetamine use disorder","author":"Truong","year":"2021","journal-title":"Am J Addict."},{"key":"B36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/YIC.0000000000000284","article-title":"Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection","volume":"35","author":"de Berardis","year":"2020","journal-title":"Int Clin Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/pcn.13094","article-title":"Cariprazine treatment of borderline personality disorder: a case report","volume":"74","author":"Grant","year":"2020","journal-title":"Psychiatry Clin Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41583-018-0029-9","article-title":"Neuroscience of apathy and anhedonia: a transdiagnostic approach","volume":"19","author":"Husain","year":"2018","journal-title":"Nat Rev Neurosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1176\/appi.neuropsych.11030057","article-title":"Longitudinal evaluation of neuropsychiatric symptoms in huntington's disease","volume":"24","author":"Thompson","year":"2012","journal-title":"J Neuro Clin Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0460.1000431","article-title":"Apathy in huntington's disease: a review of the current conceptualization","volume":"8","author":"Camacho","year":"2018","journal-title":"J Alzheimer's Dis Parkinsonism."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","article-title":"Timing and impact of psychiatric, cognitive, and motor abnormalities in huntington disease","volume":"96","author":"McAllister","year":"2021","journal-title":"Neurology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1176\/jnp.10.3.314","article-title":"Apathy is not depression","volume":"10","author":"Levy","year":"1998","journal-title":"J Neuro Clin Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/893905","article-title":"Dysthymia and apathy: diagnosis and treatment","volume":"2011","author":"Ishizaki","year":"2011","journal-title":"Dep Res Treat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1176\/jnp.3.3.243","article-title":"Apathy: a neuropsychiatric syndrome","volume":"3","author":"Marin","year":"1991","journal-title":"J Neuro Clin Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/wps.20385","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"16","author":"Marder","year":"2017","journal-title":"World Psychiatry."},{"key":"B46","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders.","year":"1993"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2019.00710","article-title":"International guidelines for the treatment of huntington's disease","volume":"10","author":"Bachoud-L\u00e9vi","year":"2019","journal-title":"Front Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"104958","DOI":"10.1016\/j.nbd.2020.104958","article-title":"Why woody got the blues: the neurobiology of depression in Huntington's disease","volume":"142","author":"Gubert","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/NDT.S4165","article-title":"Aripiprazole in the treatment of Huntington's disease: a case series","volume":"5","author":"Ciammola","year":"2009","journal-title":"Neuro Dis Treat."},{"key":"B50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/14737175.2015.1025383","article-title":"Dopamine and Huntington's disease","volume":"15","author":"Schwab","year":"2015","journal-title":"Exp Rev Neurother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0165-0173(98)00019-8","article-title":"What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?","volume":"28","author":"Berridge","year":"1998","journal-title":"Brain Res Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation","volume":"5","author":"Wise","year":"2004","journal-title":"Nat Rev Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyg.2021.628416","article-title":"Cognitive control, cognitive biases and emotion regulation in depression: a new proposal for an integrative interplay model","volume":"12","author":"Villalobos","year":"2021","journal-title":"Front Psychol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyg.2012.00449","article-title":"Neural systems for cognitive and emotional processing in posttraumatic stress disorder","volume":"3","author":"Brown","year":"2012","journal-title":"Front Psychol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/jnnp.2008.155846","article-title":"Emotion recognition in progressive supranuclear palsy","volume":"80","author":"Ghosh","year":"2009","journal-title":"J Neurol Neuro Psychiatry."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/mds.23868","article-title":"Executive functions in Parkinson's disease: systematic review and meta-analysis","volume":"26","author":"Kudlicka","year":"2011","journal-title":"Mov Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1016\/j.parkreldis.2015.09.019","article-title":"The contribution of white matter lesions (WML) to Parkinson's disease cognitive impairment symptoms: a critical review of the literature","volume":"22","author":"Vesel\u00fd","year":"2016","journal-title":"Parkinsonism Rel Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jns.2015.06.037","article-title":"Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: a systematic review","volume":"356","author":"Alzahrani","year":"2015","journal-title":"J Neurol Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1176\/jnp.2010.22.2.196","article-title":"\u201cFrontal\u201d behaviors before the diagnosis of huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness","volume":"22","author":"Duff","year":"2010","journal-title":"J Neuro Clin Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.678652","article-title":"Mild cognitive impairment as an early landmark in huntington's disease","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in huntington disease: diagnosis and treatment","volume":"11","author":"Paulsen","year":"2011","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/cercor\/bhj043","article-title":"Apathy and the functional anatomy of the prefrontal cortex\u2013basal ganglia circuits","volume":"16","author":"Levy","year":"2006","journal-title":"Cerebral Cortex."},{"key":"B63","first-page":"9","article-title":"Some theoretical and practical aspects of the disturbances of consciousness with special reference to akinetic mutism","volume":"3","author":"N\u00e9meth","year":"1988","journal-title":"Funct Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0028-3932(02)00108-2","article-title":"Motivation, reward, and Parkinson's disease: influence of dopatherapy","volume":"40","author":"Czernecki","year":"2002","journal-title":"Neuropsychologia."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s10072-014-2061-5","article-title":"Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system","volume":"36","author":"Blundo","year":"2015","journal-title":"Neurol Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/mds.21949","article-title":"Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom","volume":"23","author":"Czernecki","year":"2008","journal-title":"Mov Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/BF00449910","article-title":"Akinetic mutism associated with bicingular lesions: clinicopathological and functional anatomical correlates","volume":"237","author":"N\u00e9meth","year":"1988","journal-title":"Eur Arch Psychiatry Neuro Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"A47","DOI":"10.1136\/jnnp-2014-309032.133","article-title":"E30 brain metabolic correlates of apathy and depression in pre-manifested huntington's disease: a 18-fgd pet study","volume":"85","author":"Martinez-Horta","year":"2014","journal-title":"J Neurol Neuro Psychiatry."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.712555","article-title":"Volumetric MRI-based biomarkers in huntington's disease: an evidentiary review","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front Neurol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1212\/WNL.50.1.252","article-title":"Frontal lobe volume in patients with Huntington's disease","volume":"50","author":"Aylward","year":"1998","journal-title":"Neurology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3233\/JPD-150535","article-title":"Apathy and impulse control disorders: yin &amp; yang of dopamine dependent behaviors","volume":"5","author":"Sierra","year":"2015","journal-title":"J Parkinson's Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41537-019-0087-7","article-title":"Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia","volume":"5","author":"Sekiguchi","year":"2019","journal-title":"Npj Schizophrenia."},{"key":"B73","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1523\/JNEUROSCI.0310-17.2017","article-title":"D3 receptors regulate excitability in a unique class of prefrontal pyramidal cells","volume":"37","author":"Clarkson","year":"2017","journal-title":"J Neurosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41583-020-0315-1","article-title":"The human motor cortex microcircuit: insights for neurodegenerative disease","volume":"21","author":"McColgan","year":"2020","journal-title":"Nat Rev Neurosci."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.825532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T06:13:21Z","timestamp":1644473601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.825532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":74,"alternative-id":["10.3389\/fpsyt.2021.825532"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.825532","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"article-number":"825532"}}